MYL up +1.54% percent Today $MYL High is at 54.10 and the Low 52.44 with current volume of 841,615.
Recent News posted below.
Mylan Inc MYL other info.
http://investorshangout.com/Mylan-Inc-MYL-54841/
MYL Mylan Inc Recent Headline News
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 93.11 (+2.05), IPXL: 29.00 (+0.43), KBIO: 1.93 (+0.13), MYL: 53.85 (+0.74)
Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST
ZTS: 40.20 (-0.03), ACT: 245.91 (unch), MYL: 53.85 (+0.74)
Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
PR Newswire - Fri Nov 07, 7:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
MYL: 53.85 (+0.74)
Mylan reports market availability of generic Loestrin 24 Fe for contraception
M2 - Thu Nov 06, 7:27AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the introduction of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate in the US with immediate effect.
MYL: 53.85 (+0.74)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 93.11 (+2.05), ACT: 245.91 (unch), MYL: 53.85 (+0.74), TEVA: 58.10 (+0.40)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.44 (+0.20), BCR: 163.25 (+0.87), INCY: 70.74 (+1.42), MYL: 53.85 (+0.74), AEGR: 21.60 (+0.02)
Mylan Launches Generic Loestrin 24 Fe®
PR Newswire - Wed Nov 05, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.
MYL: 53.85 (+0.74)
Mylan Is Near All-Time High Levels But Still A Strong Buy
Kanak Kanti De - at Seeking Alpha - Mon Nov 03, 12:10PM CST
MYL: 53.85 (+0.74)
Watch for Shares of Mylan (MYL) to Approach Resistance at $53.74
Comtex SmarTrend(R) - Fri Oct 31, 12:59PM CDT
Shares of Mylan (NASDAQ:MYL) have bullishly opened above the pivot of $51.77 today and have reached the first resistance level of $53.06. Analysts will be watching for a cross of the next upside pivot targets of $53.74 and $55.71.
MYL: 53.85 (+0.74)
Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.00 (+0.43), ACT: 245.91 (unch), MYL: 53.85 (+0.74), TEVA: 58.10 (+0.40)
Mylan updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:38AM CDT
MYL: 53.85 (+0.74)
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 44.07 (+0.70), SHPG: 201.00 (+2.42), MYL: 53.85 (+0.74), ABBV: 63.75 (+2.25)
Mylan (MYL) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 10:16AM CDT
The following Mylan (MYL) conference call took place on October 30, 2014, 04:30 PM ET. This is a transcript of that earnings call:
MYL: 53.85 (+0.74)
Stocks Surge At Starting Bell; Mylan, Expedia, GoPro Rocket
at Investor's Business Daily - Fri Oct 31, 9:36AM CDT
Stocks sprinted out of the starting gate Friday, with economic news, quarterly reports and international markets all adding lift. The Nasdaq staked out an early lead, up 1.2%, asMylan (MYL), Analog Devices (ADI) and Expedia (EXPE) all opened more...
AMBA: 49.05 (+1.91), GPRO: 75.43 (-3.63), EXPE: 86.15 (+1.04), ADI: 50.35 (+0.11), MYL: 53.85 (+0.74), MELI: 136.33 (+1.58)
Mylan (MYL) Highlighted As Momo Momentum Stock
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Mylan (MYL) as a momo momentum candidate
MYL: 53.85 (+0.74)
Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 93.11 (+2.05), ABT: 44.07 (+0.70), ACT: 245.91 (unch), MYL: 53.85 (+0.74)
Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.85 (+0.74), TEVA: 58.10 (+0.40)
Mylan's (MYL) CEO Heather Bresch on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:30PM CDT
MYL: 53.85 (+0.74)
MYLAN
at Investor's Business Daily - Thu Oct 30, 6:13PM CDT
MYLAN (MYL), a drugmaker, said Q3 EPS rose 41.5% to $1.16, topping views by 2 cents, and sales grew 17.9% to $2.08 bil, beating forecasts for $2.06 bil. Shares rose 1.2% to 53.
MYL: 53.85 (+0.74)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 93.11 (+2.05), ACT: 245.91 (unch), PFE: 30.25 (+0.33), MYL: 53.85 (+0.74)
Recent News posted below.
Mylan Inc MYL other info.
http://investorshangout.com/Mylan-Inc-MYL-54841/
MYL Mylan Inc Recent Headline News
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 93.11 (+2.05), IPXL: 29.00 (+0.43), KBIO: 1.93 (+0.13), MYL: 53.85 (+0.74)
Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST
ZTS: 40.20 (-0.03), ACT: 245.91 (unch), MYL: 53.85 (+0.74)
Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
PR Newswire - Fri Nov 07, 7:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
MYL: 53.85 (+0.74)
Mylan reports market availability of generic Loestrin 24 Fe for contraception
M2 - Thu Nov 06, 7:27AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the introduction of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate in the US with immediate effect.
MYL: 53.85 (+0.74)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 93.11 (+2.05), ACT: 245.91 (unch), MYL: 53.85 (+0.74), TEVA: 58.10 (+0.40)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.44 (+0.20), BCR: 163.25 (+0.87), INCY: 70.74 (+1.42), MYL: 53.85 (+0.74), AEGR: 21.60 (+0.02)
Mylan Launches Generic Loestrin 24 Fe®
PR Newswire - Wed Nov 05, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.
MYL: 53.85 (+0.74)
Mylan Is Near All-Time High Levels But Still A Strong Buy
Kanak Kanti De - at Seeking Alpha - Mon Nov 03, 12:10PM CST
MYL: 53.85 (+0.74)
Watch for Shares of Mylan (MYL) to Approach Resistance at $53.74
Comtex SmarTrend(R) - Fri Oct 31, 12:59PM CDT
Shares of Mylan (NASDAQ:MYL) have bullishly opened above the pivot of $51.77 today and have reached the first resistance level of $53.06. Analysts will be watching for a cross of the next upside pivot targets of $53.74 and $55.71.
MYL: 53.85 (+0.74)
Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.00 (+0.43), ACT: 245.91 (unch), MYL: 53.85 (+0.74), TEVA: 58.10 (+0.40)
Mylan updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:38AM CDT
MYL: 53.85 (+0.74)
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 44.07 (+0.70), SHPG: 201.00 (+2.42), MYL: 53.85 (+0.74), ABBV: 63.75 (+2.25)
Mylan (MYL) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 10:16AM CDT
The following Mylan (MYL) conference call took place on October 30, 2014, 04:30 PM ET. This is a transcript of that earnings call:
MYL: 53.85 (+0.74)
Stocks Surge At Starting Bell; Mylan, Expedia, GoPro Rocket
at Investor's Business Daily - Fri Oct 31, 9:36AM CDT
Stocks sprinted out of the starting gate Friday, with economic news, quarterly reports and international markets all adding lift. The Nasdaq staked out an early lead, up 1.2%, asMylan (MYL), Analog Devices (ADI) and Expedia (EXPE) all opened more...
AMBA: 49.05 (+1.91), GPRO: 75.43 (-3.63), EXPE: 86.15 (+1.04), ADI: 50.35 (+0.11), MYL: 53.85 (+0.74), MELI: 136.33 (+1.58)
Mylan (MYL) Highlighted As Momo Momentum Stock
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Mylan (MYL) as a momo momentum candidate
MYL: 53.85 (+0.74)
Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 93.11 (+2.05), ABT: 44.07 (+0.70), ACT: 245.91 (unch), MYL: 53.85 (+0.74)
Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.85 (+0.74), TEVA: 58.10 (+0.40)
Mylan's (MYL) CEO Heather Bresch on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:30PM CDT
MYL: 53.85 (+0.74)
MYLAN
at Investor's Business Daily - Thu Oct 30, 6:13PM CDT
MYLAN (MYL), a drugmaker, said Q3 EPS rose 41.5% to $1.16, topping views by 2 cents, and sales grew 17.9% to $2.08 bil, beating forecasts for $2.06 bil. Shares rose 1.2% to 53.
MYL: 53.85 (+0.74)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 93.11 (+2.05), ACT: 245.91 (unch), PFE: 30.25 (+0.33), MYL: 53.85 (+0.74)
